Ya-Min Tsai

Ya-Min Tsai

Auto-generated profile, based on publicly available information

Ya-Min Tsai

College of Medicine, National Taiwan University 2 Department of Clinical Laboratory Sciences and Medical Biotechnology Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2022 in Science Translational Medicine
Verified
Journal Article
Open access
HHHan-Yi Huang
Han-Yi Huang
HLHsin-Yu Liao
Hsin-Yu Liao
XCXiaorui Chen
Xiaorui Chen
SWSzu-Wen Wang
Szu-Wen Wang
CCCheng-Wei Cheng
Cheng-Wei Cheng
CWChi-Huey Wong
Chi-Huey Wong
A major challenge to end the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to develop a broadly protective vaccine that elicits long-term immunity. As the key immunogen, the viral surface spike (S) protein is frequently mutated, and conserved epitopes are shielded by glycans. Here, we revealed that S protein glycosylation has site-differential effects on viral infectivity. We found that S protein generated by lung epithelial cells has glycoforms associated with increased infectivity. Compared to the fully glycosylated S protein, immunization of S protein with N-glycans trimmed to the mono-GlcNAc–decorated state (S MG ) elicited stronger immune responses and better protection for human angiotensin-converting enzyme 2 (hACE2) transgenic mice against variants of concern (VOCs). In addition, a broadly neutralizing monoclonal antibody was identified from S MG -immunized mice that could neutralize wild-type SARS-CoV-2 and VOCs with subpicomolar potency. Together, these results demonstrate that removal of glycan shields to better expose the conserved sequences has the potential to be an effective and simple approach for developing a broadly protective SARS-CoV-2 vaccine.

21 February 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
YCYi‐Chung Chang
Yi‐Chung Chang
CYChi‐Fan Yang
Chi‐Fan Yang
YCYi‐Fen Chen
Yi‐Fen Chen
CYChia‐Chun Yang
Chia‐Chun Yang
YCYuan‐Lin Chou
Yuan‐Lin Chou
PYPan‐Chyr Yang
Pan‐Chyr Yang
The emergence of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) variants has altered the trajectory of the COVID‐19 pandemic and raised some uncertainty on the long‐term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS‐CoV‐2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS‐CoV‐2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC 50 in vitro . Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18‐hACE2‐transgenic mice, accompanied by a significant prevention of virus‐associated extensive pulmonary alveolar damage, vascular thrombi, and immune cell infiltrations. Our data suggest that C6G25S provides an alternative and effective approach to combating the COVID‐19 pandemic.

9 May 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YLYou-Sheng Lin
You-Sheng Lin
YCYung-Chi Chang
Yung-Chi Chang
TCTai-Ling Chao
Tai-Ling Chao
YTYa-Min Tsai
Ya-Min Tsai
SJShu-Jhen Jhuang
Shu-Jhen Jhuang
LHLi-Chung Hsu
Li-Chung Hsu
Type I interferons are important antiviral cytokines, but prolonged interferon production is detrimental to the host. The TLR3-driven immune response is crucial for mammalian antiviral immunity, and its intracellular localization determines induction of type I interferons; however, the mechanism terminating TLR3 signaling remains obscure. Here, we show that the E3 ubiquitin ligase ZNRF1 controls TLR3 sorting into multivesicular bodies/lysosomes to terminate signaling and type I interferon production. Mechanistically, c-Src kinase activated by TLR3 engagement phosphorylates ZNRF1 at tyrosine 103, which mediates K63-linked ubiquitination of TLR3 at lysine 813 and promotes TLR3 lysosomal trafficking and degradation. ZNRF1-deficient mice and cells are resistant to infection by encephalomyocarditis virus and SARS-CoV-2 because of enhanced type I interferon production. However, Znrf1−/− mice have exacerbated lung barrier damage triggered by antiviral immunity, leading to enhanced susceptibility to respiratory bacterial superinfections. Our study highlights the c-Src–ZNRF1 axis as a negative feedback mechanism controlling TLR3 trafficking and the termination of TLR3 signaling.

28 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
YHYu-Ting Hsieh
Yu-Ting Hsieh
TTTsung-Lin Tsai
Tsung-Lin Tsai
嘉涂嘉峻 涂
嘉峻 涂
SHShen-Yan Huang
Shen-Yan Huang
JHJian-Wen Heng
Jian-Wen Heng
CHChia-Lin Hsu
Chia-Lin Hsu
An increasing body of evidence emphasizes the role of metabolic reprogramming in immune cells to fight off infections. However, little is known about the regulation of metabolite transporters that facilitate and support metabolic demands. In this study, we found that equilibrative nucleoside transporter 3 (ENT3) expression is part of the innate immune response, and is rapidly upregulated upon bacterial and viral infection. The transcription of ENT3 is directly under the regulation of IFN-induced signaling, positioning this metabolite transporter as an Interferon-stimulated gene (ISG). Moreover, we unveil that several viruses, including SARS-CoV2, require ENT3 to facilitate their entry into the cytoplasm. The removal or suppression of ENT3 expression is sufficient to significantly decrease viral replication in vitro and in vivo.